Attached files

file filename
EX-10.31.1 - NOVARTIS FIRST AMENDMENT TO LICENSE AGREEMENT - Endo International plcex-10311novartisconsumerhe.htm
EX-10.308 - SUPPLEMENTAL INDENTURE 5.75% 2022 NOTES - Endo International plcex-10308supp_indenturex5x7.htm
EX-10.305 - RRA 2023 NOTES - Endo International plcex-10305rra_counterpartx5x.htm
EX-10.301 - RRA 2020 NOTES - Endo International plcex-10301rracounterpart_7x0.htm
EX-10.31 - NOVARTIS LICENSE AGREEMENT - Endo International plcex-1031novartisconsumerhea.htm
EX-10.307 - RRA 2025 NOTES - Endo International plcex-10307rra_counterpartx6x.htm
EX-10.309 - SUPPLEMENTAL INDENTURE 6.00% 2023 NOTES - Endo International plcex-10309supp_indenturex6x0.htm
EX-10.310 - CAMPANELLI EMPLOYMENT AGREEMENT - Endo International plcex-10310employmentagreemen.htm
EX-10.304 - SUPPLEMENTAL INDENTURE 2023 NOTES - Endo International plcex-10304supp_indenturex5x3.htm
EX-10.302 - SUPPLEMENTAL INDENTURE 2022 NOTES - Endo International plcex-10302supp_indenturex7x2.htm
EX-10.306 - SUPPLEMENTAL INDENTURE 2025 NOTES - Endo International plcex-10306suppindenture_6x00.htm
EX-10.303 - RRA 2022 NOTES - Endo International plcex-10303rracounterpart7_25.htm
EX-31.2 - CFO SECTION 302 CERTIFICATION - Endo International plcex3129302015cfo302cert.htm
EX-31.1 - CEO SECTION 302 CERTIFICATION - Endo International plcex3119302015ceo302cert.htm
EX-32.2 - CFO SECTION 906 CERTIFICATION - Endo International plcex3229302015cfo906cert.htm
10-Q - 10-Q - Endo International plcendp-9302015x10q.htm
EX-10.300 - SUPPLEMENTAL INDENTURE 2020 NOTES - Endo International plcex-10300supp_indenturex7x0.htm
EX-10.31.2 - NOVARTIS SECOND AMENDMENT TO LICENSE AGREEMENT - Endo International plcex-10312novartisconsumerhe.htm
Exhibit 32.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER
PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
I, Rajiv De Silva, as President and Chief Executive Officer of Endo International plc (the Company), hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
(1) The Quarterly Report on Form 10-Q of the Company for the quarterly period ended September 30, 2015 (the Report) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m); and
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
 
 
 
 
 
 
/S/ RAJIV DE SILVA
Name:
 
Rajiv De Silva
Title:
 
President and Chief Executive Officer
(Principal Executive Officer)
Date: November 9, 2015
A signed original of this written statement required by Section 906 has been provided to, and will be retained by, Endo International plc and furnished to the Securities and Exchange Commission or its staff upon request.